Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2011 Apr 9

PMID 21474585

Citations 297

Authors

Brad Spellberg

Martin Blaser

Robert J Guidos

Helen W Boucher

John S Bradley

Barry I Eisenstein

Dale Gerding

Ruth Lynfield

L Barth Reller

John Rex

David Schwartz

Edward Septimus

Fred C Tenover

David N Gilbert

Affiliations

Soon will be listed here.

Citing Articles

The prevalence and distribution of aminoglycoside resistance genes.

Zhang Y, Zhang N, Wang M, Luo M, Peng Y, Li Z Biosaf Health. 2025; 5(1):14-20.

PMID: 40078603 PMC: 11895043. DOI: 10.1016/j.bsheal.2023.01.001.

Utility of Artificial Intelligence in Antibiotic Development: Accelerating Discovery in the Age of Resistance.

Zavaleta-Monestel E, Rojas-Chinchilla C, Campos-Hernandez J, Martinez-Vargas E Cureus. 2025; 17(1):e78296.

PMID: 40027042 PMC: 11872168. DOI: 10.7759/cureus.78296.

Insights into kinetic and regression models developed to estimate the abundance of antibiotic-resistant genes during biological digestion of wastewater sludge.

Poorasgari E, Ormeci B J Water Health. 2025; 23(2):238-259.

PMID: 40018965 DOI: 10.2166/wh.2025.372.

Antimicrobial Susceptibility Profiles of Commensal spp. Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023.

Kovacs L, Szabo A, Barnacz F, Csirmaz B, Jerzsele A, Kerek A Antibiotics (Basel). 2025; 14(2).

PMID: 40001443 PMC: 11851855. DOI: 10.3390/antibiotics14020200.

Systematic review of multidrug-resistant in the Arabian Peninsula: molecular epidemiology and resistance patterns.

Idrees E, Aldriwesh M, Alkhulaifi M, Alghoribi M Front Microbiol. 2025; 16:1489317.

PMID: 39927260 PMC: 11802542. DOI: 10.3389/fmicb.2025.1489317.

References

Hoffmann M, Eber M, Laxminarayan R . Increasing resistance of acinetobacter species to imipenem in United States hospitals, 1999-2006. Infect Control Hosp Epidemiol. 2009; 31(2):196-7. DOI: 10.1086/650379. View

Rodriguez-Bano J, Picon E, Gijon P, Hernandez J, Ruiz M, Pena C . Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2009; 50(1):40-8. DOI: 10.1086/649537. View

Morel C, Mossialos E . Stoking the antibiotic pipeline. BMJ. 2010; 340:c2115. DOI: 10.1136/bmj.c2115. View

Kumarasamy K, Toleman M, Walsh T, Bagaria J, Butt F, Balakrishnan R . Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010; 10(9):597-602. PMC: 2933358. DOI: 10.1016/S1473-3099(10)70143-2. View

LEDERBERG J . Infectious history. Science. 2000; 288(5464):287-93. DOI: 10.1126/science.288.5464.287. View

Higgins P, Dammhayn C, Hackel M, Seifert H . Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2009; 65(2):233-8. DOI: 10.1093/jac/dkp428. View

Rodriguez-Bano J, Alcala J, Cisneros J, Grill F, Oliver A, Horcajada J . Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008; 168(17):1897-902. DOI: 10.1001/archinte.168.17.1897. View

Park Y, Jung S, Park K, Cheong H, Peck K, Song J . Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis. 2009; 64(1):43-51. DOI: 10.1016/j.diagmicrobio.2009.01.012. View

Projan S . Why is big Pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol. 2003; 6(5):427-30. DOI: 10.1016/j.mib.2003.08.003. View

10.

Ayanruoh S, Waseem M, Quee F, Humphrey A, Reynolds T . Impact of rapid streptococcal test on antibiotic use in a pediatric emergency department. Pediatr Emerg Care. 2009; 25(11):748-50. DOI: 10.1097/PEC.0b013e3181bec88c. View

11.

Young R . Cancer clinical trials--a chronic but curable crisis. N Engl J Med. 2010; 363(4):306-9. DOI: 10.1056/NEJMp1005843. View

12.

Scoggins J, Ramsey S . A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst. 2010; 102(17):1371. PMC: 2935476. DOI: 10.1093/jnci/djq291. View

13.

Filice G, Nyman J, Lexau C, Lees C, Bockstedt L, Como-Sabetti K . Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010; 31(4):365-73. DOI: 10.1086/651094. View

14.

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1):84-93. DOI: 10.1164/rccm.200512-1922OC. View

15.

CHRISTIE R . Penicillin in subacute bacterial endocarditis. Br Med J. 1949; 2(4634):950. PMC: 2051567. DOI: 10.1136/bmj.2.4634.950. View

16.

Shlaes D, Moellering Jr R . The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis. 2002; 34(3):420-2. DOI: 10.1086/338976. View

17.

Temple R, Ellenberg S . Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000; 133(6):455-63. DOI: 10.7326/0003-4819-133-6-200009190-00014. View

18.

Kang C, Song J, Chung D, Peck K, Ko K, Yeom J . Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2010; 36(3):284-7. DOI: 10.1016/j.ijantimicag.2010.05.009. View

19.

Muratani T, Matsumoto T . Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int J Antimicrob Agents. 2006; 28 Suppl 1:S10-3. DOI: 10.1016/j.ijantimicag.2006.05.009. View

20.

Powers J . Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions. Stat Med. 2008; 27(3):343-52. DOI: 10.1002/sim.3138. View